transfusion independence hmga2 activation gene therapy human beta-thalassaemia 
beta-haemoglobinopathies prevalent inherited disorders worldwide gene therapy beta-thalassaemia particularly challenging given requirement massive haemoglobin production lineage-specific manner lack selective advantage corrected haematopoietic stem cells compound betae/beta0-thalassaemia common form severe thalassaemia southeast asian countries diasporas12 betae-globin allele bears point mutation causes alternative splicing abnormally spliced form non-coding whereas correctly spliced messenger rna expresses mutated betae-globin partial instability12 compounded non-functional beta0 allele profound decrease beta-globin synthesis results approximately half betae/beta0-thalassaemia patients transfusion-dependent12 available curative therapy allogeneic haematopoietic stem cell transplantation although patients human-leukocyte-antigen-matched geno-identical donor still risk rejection graft-versus-host disease show months lentiviral beta-globin gene transfer adult patient severe betae/beta0-thalassaemia dependent monthly transfusions since early childhood become transfusion independent past months blood haemoglobin maintained g dl- one-third contains vector-encoded beta-globin therapeutic benefit results dominant myeloid-biased cell clone integrated vector causes transcriptional activation hmga2 erythroid cells increased expression truncated hmga2 mrna insensitive degradation let- micrornas clonal dominance accompanies therapeutic efficacy may coincidental stochastic result froma hitherto benign cell expansion caused dysregulation hmga2 gene stem/progenitor cells 
